Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection.
COVID-19
Mortality
SARS-CoV-2 infection
Surfactant protein-D (SP-D)
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
05
08
2022
revised:
11
10
2022
accepted:
16
10
2022
pubmed:
8
11
2022
medline:
16
11
2022
entrez:
7
11
2022
Statut:
ppublish
Résumé
Surfactant protein-D (SP-D) is a lung-resident protein that has emerged as a potential biomarker for COVID-19. Previous investigations on acute respiratory distress syndrome patients demonstrated a significant increment of SP-D serum levels in pathological conditions. Since SP-D is not physiologically permeable to alveoli-capillary membrane and poorly expressed by other tissues, this enhancement is likely due to an impairment of the pulmonary barrier caused by prolonged inflammation. A retrospective study on a relatively large cohort of patients of Hospital Pio XI of Desio was conducted to assess differences of the hematic SP-D concentrations among COVID-19 patients and healthy donors and if SP-D levels resulted a risk factor for disease severity and mortality. The first analysis, using an ANOVA-model, showed a significant difference in the mean of log SP-D levels between COVID-19 patients and healthy donors. Significant variations were also found between dead vs survived patients. Results confirm that SP-D concentrations were significantly higher for both hospitalized COVID-19 and dead patients, with threshold values of 150 and 250 ng/mL, respectively. Further analysis conducted with Logistic Mixed models, highlighted that higher SP-D levels at admission and increasing differences among follow-up and admission values resulted the strongest significant risk factors of mortality (model predictive accuracy, AUC = 0.844). The results indicate that SP-D can be a predictive marker of COVID-19 disease and its outcome. Considering its prognostic value in terms of mortality, the early detection of SP-D levels and its follow-up in hospitalized patients should be considered to direct the therapeutic intervention.
Sections du résumé
BACKGROUND
BACKGROUND
Surfactant protein-D (SP-D) is a lung-resident protein that has emerged as a potential biomarker for COVID-19. Previous investigations on acute respiratory distress syndrome patients demonstrated a significant increment of SP-D serum levels in pathological conditions. Since SP-D is not physiologically permeable to alveoli-capillary membrane and poorly expressed by other tissues, this enhancement is likely due to an impairment of the pulmonary barrier caused by prolonged inflammation.
METHODS
METHODS
A retrospective study on a relatively large cohort of patients of Hospital Pio XI of Desio was conducted to assess differences of the hematic SP-D concentrations among COVID-19 patients and healthy donors and if SP-D levels resulted a risk factor for disease severity and mortality.
RESULTS
RESULTS
The first analysis, using an ANOVA-model, showed a significant difference in the mean of log SP-D levels between COVID-19 patients and healthy donors. Significant variations were also found between dead vs survived patients. Results confirm that SP-D concentrations were significantly higher for both hospitalized COVID-19 and dead patients, with threshold values of 150 and 250 ng/mL, respectively. Further analysis conducted with Logistic Mixed models, highlighted that higher SP-D levels at admission and increasing differences among follow-up and admission values resulted the strongest significant risk factors of mortality (model predictive accuracy, AUC = 0.844).
CONCLUSIONS
CONCLUSIONS
The results indicate that SP-D can be a predictive marker of COVID-19 disease and its outcome. Considering its prognostic value in terms of mortality, the early detection of SP-D levels and its follow-up in hospitalized patients should be considered to direct the therapeutic intervention.
Identifiants
pubmed: 36341812
pii: S0009-8981(22)01347-X
doi: 10.1016/j.cca.2022.10.013
pmc: PMC9617654
pii:
doi:
Substances chimiques
Pulmonary Surfactant-Associated Protein D
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-145Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Am J Respir Crit Care Med. 2000 Jul;162(1):258-63
pubmed: 10903251
PLoS Biol. 2008 Nov 11;6(11):e266
pubmed: 19007302
Lung. 2015 Feb;193(1):25-30
pubmed: 25537934
Health Sci Rep. 2022 Apr 25;5(3):e622
pubmed: 35509408
BMJ Open. 2016 Oct 12;6(10):e011797
pubmed: 27733410
Lung. 2020 Oct;198(5):777-784
pubmed: 32918573
J Infect Dis. 2021 Jul 2;224(1):21-30
pubmed: 33668070
Lung. 2013 Jun;191(3):295-303
pubmed: 23435873
Front Med (Lausanne). 2018 Feb 08;5:18
pubmed: 29473039
Am J Respir Crit Care Med. 1999 Dec;160(6):1843-50
pubmed: 10588595
Biochim Biophys Acta. 1998 Nov 19;1408(2-3):278-89
pubmed: 9813367
Respir Res. 2000;1(2):93-108
pubmed: 11667972
J Infect Dis. 2012 Dec 1;206(11):1685-94
pubmed: 22829640
J Med Virol. 2021 Oct;93(10):6008-6015
pubmed: 34232533
Scand J Immunol. 2009 Jun;69(6):508-15
pubmed: 19439011
Acta Med Acad. 2022 Apr;51(1):21-28
pubmed: 35695399
Front Immunol. 2021 Jan 19;11:622598
pubmed: 33542724
Eur J Clin Invest. 2006 Jun;36(6):423-35
pubmed: 16684127
Eur Respir J. 2001 Mar;17(3):481-7
pubmed: 11405529
Biomolecules. 2021 Jul 28;11(8):
pubmed: 34439781
Scand J Clin Lab Invest. 2021 Feb;81(1):18-23
pubmed: 33403882
Respir Med. 2015 Dec;109(12):1576-81
pubmed: 26481343
BMC Infect Dis. 2021 Aug 3;21(1):737
pubmed: 34344306
Thorax. 2003 Nov;58(11):983-8
pubmed: 14586055
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
J Biol Chem. 1996 Aug 2;271(31):18912-9
pubmed: 8756121